Multi-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics

Summary

Major Depressive Disorder is one of the most common mental diseases,which increases health-care costs and the financial burden to families and societies. Considering its complex clinical symptoms and diversity of comorbidity, depressive disorder's recognition，diagnosis，and antihistone are based on symptomatology,which is lack of multidimensional diagnosis technique based on clinical pathological characteristics,as well as lack of individualized therapy strategy based on quantified evaluation. Besides, other physical diseases，such as nervous system diseases, cardiovascular diseases，endocrine diseases, have the high comorbidity of depressive disorder. However，there is no precise diagnosis technique or standardized therapy strategy. With all those taken into consideration,our study is aimed to adopt E-mental health and m-Health to explore multi-dimensional diagnosis, individualized therapy and management technique based on molecular biology,nerve electrophysiology，and neuroimaging technology etc.

Conditions

• Depressive Disorder

Interventions

DRUG

Fluoxetine

Fluoxetine is one kind of selective serotonin reuptake inhibitor(SSRIs), whose effect is much better than other non-underload subtypes compared with underload subtypes.So patients would be treated with fluoxetine only.

COMBINATION_PRODUCT

fluoxetine + cognitive-behavioral treatment（CBT）

the investigators would recommend fluoxetine to help to cure depressive disorder.And CBT is a very effective way for patients to alleviate or relieve clinical symptoms during episode stage.

DRUG

fluoxetine + Amfebutamone

Amfebutamone is one kind of SNRIs, and it shows much better therapy effect on patients with exhaustion /dizziness.So the investigators recommend these two drugs to help to cure patients with depressive disorder.

COMBINATION_PRODUCT

physical treatment+fluoxetine+amfebutamone

the investigators recommend drug(fluoxetine and amfebutamone) and physical treatment as intervention.

DRUG

Fluvoxamine

Fluvoxamine could inhibit CYP1A2 and CYP2C19 and affect the metabolism of melatonin, and help to release symptoms of depressive disorder with sleep problems.

DRUG

Lithium+fluvoxamine

the investigators recommend lithium as a mood stabilizer and use fluvoxamine to affect the level of melatonin.

COMBINATION_PRODUCT

fluvoxamine + lithium + physical therapy

the investigators recommend depressants and mood stabilizers as well as physical therapy to help to cure depressive disorder.

COMBINATION_PRODUCT

Cognitive behavior treatment +fluvoxamine

the investigators recommend behavioral therapy as well as drugs.

DRUG

Mirtazapine/SNRIs

Mirtazapine is one kind of antagonist of a2 adrenergic receptors and could block 5-hydroxytryptamine2 and 5-hydroxytryptamine3,help to release symptoms like anxiety or somatization.Besides, SNRIs could also make similar effect on patients.Therefore, the investigators recommend mirtazapine/SNRIs to treat patients with depressive disorder.

COMBINATION_PRODUCT

mirtazapine+ Cognitive behavior treatment

the investigators recommend CBT and mirtazapine as interventions.The dosage and frequency would depend on patients' severity of symptoms .

DRUG

mirtazapine + SNRIs

the investigator recommend mirtazapine and SNRIs to treat patients with major depressive disorder.

COMBINATION_PRODUCT

mirtazapine + SNRIs + physical therapy

the investigators would manage to use drugs and physical treatment to help to release the symptoms of depressive disorder.

OTHER

TAU(treat as usual)

patients in this group would receive therapy strategies according to their symptoms and preference.

Sponsors & Collaborators

• Shanghai Jiao Tong University School of Medicine

  collaborator OTHER

• Chinese Academy of Sciences

  collaborator OTHER_GOV

• Shanxi Medical University

  collaborator OTHER

• Central South University

  collaborator OTHER

• Second Military Medical University

  collaborator OTHER

• Peking University Sixth Hospital

  collaborator OTHER

• First Affiliated Hospital Xi'an Jiaotong University

  collaborator OTHER

• First Affiliated Hospital of Kunming Medical University

  collaborator OTHER

• Air Force Military Medical University, China

  collaborator OTHER

• Zhejiang University

  collaborator OTHER

• Wuhan Mental Health Centre

  collaborator OTHER

• Corning Hospital, Shenzhen City

  collaborator UNKNOWN

• the First Specialized Subject Hospital of Harbin

  collaborator UNKNOWN

• Renmin Hospital of Wuhan University

  collaborator OTHER

• Seventh People's Hospital of Hangzhou

  collaborator OTHER

• Shandong Mental Health Center

  collaborator OTHER

• Shanghai Mental Health Center

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-08-01

Primary Completion

2019-12-31

Completion

2020-12-31

Countries

• China

Study Locations